Abbisko Cayman Limited stock analysis
Want to see HK:2256 full AI Analyst Report?
Abbisko Cayman Limited (2256) Stock Price & Analysis
2256 Stock Chart & Stats
- Day’s Range
- HKD 6.31 - HKD 6.93
- 52-Week Range
- HKD 6.04 - HKD 14.99
- Previous Close
- HKD 6.79
- Volume
- N/A
- Average Volume (3M)
- 1.94M
- Market Cap
- HKD 4.66B
- Enterprise Value
- HKD 4.48B
- Total Cash (Recent Filing)
- HKD 2.45B
- Total Debt (Recent Filing)
- HKD 454.73M
- Price to Earnings (P/E)
- ―
- Beta
- 1.19
- Next Earnings
- Mar 18, 2027 (Est.)
- EPS Estimate
- -0.53
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
The conservative capital structure gives Abbisko financial flexibility as it develops its business. Low debt relative to equity reduces balance-sheet strain and leaves greater capacity to fund operations, absorb earnings volatility, or support future investment without relying heavily on additional borrowing.
Improved Profitability
The shift from operating losses to positive EBIT and sustained positive net income marks meaningful progress in the earnings profile. Although profitability remains modest, this transition can strengthen internal funding capacity and indicates the business is moving beyond its earlier loss-making phase.
Positive Cash Generation
Positive operating and free cash flow in 2025 provides tangible support for the company’s operations and reduces dependence on external financing. Free cash flow representing about 93% of net income also shows that recent reported earnings were substantially converted into cash.
Bears Say
Revenue Contraction
Revenue contraction after strong growth in 2024 suggests that the company’s commercial momentum is not yet consistently established. A weaker top line can limit operating leverage, constrain reinvestment, and make the recent improvement in profitability more vulnerable to future volatility.
Unstable Cash Flow
The return to positive cash generation is encouraging, but the sharp annual decline and history of negative operating and free cash flow indicate that cash conversion is not yet dependable. This inconsistency can make long-term funding and investment planning less predictable.
Thin, Transitional Earnings
A relatively thin margin and the recent history of substantial losses show that earnings remain in transition rather than firmly established. Limited profitability provides less protection against operating setbacks and leaves future results more exposed to fluctuations in revenue and expenses.
Abbisko Cayman Limited News
Abbisko’s Achondroplasia Drug Wins EMA Orphan Status, Advancing Global Push
Abbisko Cayman Limited ( ($HK:2256) ) has provided an announcement. Abbisko Cayman Limited said its subsidiary Abbisko Therapeutics has received Orphan Designation from the European Medicines Agency for lavengratinib (ABSK061),
Abbisko Therapeutics Posts Encouraging Phase II Data for Pediatric Achondroplasia Drug
Abbisko Cayman Limited ( ($HK:2256) ) just unveiled an announcement. Abbisko Therapeutics has reported positive preliminary Phase II data for its FGFR2/3 inhibitor lavengratinib (ABSK061) in children aged six and
Abbisko Cayman Advances Oncology Pipeline as Lead Drug Pimicotinib Launches in China
Abbisko Cayman Limited ( ($HK:2256) ) has shared an announcement. Abbisko Cayman Limited reported substantial operational progress for the six months ended June 30, 2026, highlighted by the commercial launch
2256 FAQ
What was Abbisko Cayman Limited’s price range in the past 12 months?
What is Abbisko Cayman Limited’s market cap?
When is Abbisko Cayman Limited’s upcoming earnings report date?
How were Abbisko Cayman Limited’s earnings last quarter?
Is Abbisko Cayman Limited overvalued?
Does Abbisko Cayman Limited pay dividends?
What is Abbisko Cayman Limited’s EPS estimate?
How many shares outstanding does Abbisko Cayman Limited have?
What happened to Abbisko Cayman Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Abbisko Cayman Limited?
What is the TipRanks Smart Score and how is it calculated?
Abbisko Cayman Limited Stock Smart Score
Company Description
Abbisko Cayman Limited
Founded in 2016 and headquartered in Shanghai, People's Republic of China, Abbisko Cayman Limited operates as a clinical-stage biopharmaceutical company. Its core mission involves the discovery and advancement of small molecule oncology therapeutics. The company's development efforts primarily target small molecule precision oncology and immuno-oncology therapeutic areas. Among its prominent product candidates are ABSK011, a small molecule designed to inhibit fibroblast growth factor receptor 4, intended for advanced hepatocellular carcinoma characterized by hyper-activation of FGF19/FGFR4 signaling. Another significant asset is ABSK091, a molecularly targeted candidate addressing a range of solid tumors, including urothelial, gastric, cholangiocarcinoma, and lung cancers. Furthermore, Abbisko Cayman Limited maintains a broader pipeline of other promising product candidates.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Yao-Chang Xu
- Employees
- 286
- Website
- www.abbisko.com
- Address
- Building 3, No. 898, Shanghai, SH, 201203, CN
Abbisko Cayman Limited (2256) Earnings & Revenues
2256 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 1 | 6 | 15 |
| Technical Analysis | 1 | 6 | 3 |
| Moving Averages | 0 | 0 | 12 |









